A case of lattice corneal dystrophy type 1 with bilateral Mooren's ulcer.

Am J Ophthalmol Case Rep

Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Published: March 2023

AI Article Synopsis

  • A rare case of bilateral Mooren's ulcer in a 62-year-old male with lattice corneal dystrophy type 1 (LCD1) is reported, highlighting the patient's symptoms of pain and sensitivity to light for two months before seeking treatment.
  • The patient was diagnosed with Mooren's ulcer after examination revealed extensive corneal ulcers, leading to a treatment plan that included topical steroids, antibiotics, and systemic immunosuppressants.
  • Following surgical intervention and ongoing treatment, the patient experienced successful healing without recurrence of ulcers over more than a decade, marking a significant achievement in managing this uncommon combination of conditions.

Article Abstract

Purpose: To report a rare case of lattice corneal dystrophy type 1 (LCD1) with bilateral Mooren's ulcer.

Observations: This case involved a 62-year-old male patient with LCD1 who presented with the primary complaint of experiencing pain and photophobia in both eyes for 2 months prior to his initial visit. Upon examination, a peripheral corneal ulcer was observed in both eyes covering more than 3 of the 4 quadrants, accompanied with ciliary injection and severe corneal infiltration. He was diagnosed with Mooren's ulcer, and treatment with 0.1% betamethasone and 0.5% levofloxacin eye drops and systemic cyclosporine and betamethasone was initiated. At 1-month post treatment initiation, a remaining ulceration ridge was observed on the corneal surface in his left eye, which was subsequently resected. Complete epithelialization was achieved at 1-month postoperative in the left eye and after 6-months of conservative topical treatment in the right eye. At 8-9 years post onset of Mooren's ulcer, the patient underwent penetrating keratoplasty in both eyes while undergoing treatment with oral cyclosporine administration for severe corneal opacity due to progression of lattice dystrophy. Post treatment, there has been no recurrence of ulcerations, even though more that 10 years has passed since the onset of Mooren's ulcer.

Conclusions And Importance: To the best of our knowledge, this is the first reported case of LCD1 with bilateral Mooren's ulcer, and in this rare case, the patient was successfully treated with a combination of steroid, cyclosporine, and peripheral superficial keratectomy, and a good visual outcome was achieved after penetrating keratoplasty (PK) under the use of systemic cyclosporine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883143PMC
http://dx.doi.org/10.1016/j.ajoc.2023.101796DOI Listing

Publication Analysis

Top Keywords

mooren's ulcer
16
bilateral mooren's
12
case lattice
8
lattice corneal
8
corneal dystrophy
8
dystrophy type
8
rare case
8
lcd1 bilateral
8
severe corneal
8
systemic cyclosporine
8

Similar Publications

Risk factors for recurrence of Mooren's ulcer after keratoplasty.

Heliyon

November 2024

Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.

Purpose: The purpose of this study was to investigate the clinical characteristics of patients with corneal Mooren's ulcers (MU) and explore potential risk factors for recurrence after keratoplasty.

Methods: The study retrospectively analyzed 87 patients (101 eyes) diagnosed with MU. Factors associated with recurrence after keratoplasty were identified using correlation analysis, and a clinical scoring system was developed based on the magnitude of the univariate and multivariate logistic regression analysis.

View Article and Find Full Text PDF

[Case report of a severe Mooren's ulcer].

Ann Pathol

October 2024

Service de pathologie, CHU de Reims, 51100 Reims, France; MEDyC UMR 7369, université de Reims Champagne-Ardenne, 51100 Reims, France.

Mooren's ulcer is a painless and idiopathic ulcer of the peripheral cornea related to autoimmunity against a corneal stromal antigen, calgranulin C. Corneal involvement is isolated. There are no specific histopathological features to differentiate Mooren's ulcer from pseudo-Mooren's, the latter being part of a systemic disease.

View Article and Find Full Text PDF
Article Synopsis
  • Mooren's ulcer (MU) is a rare and serious eye condition that causes crescent-shaped corneal ulcers, which can lead to blindness if untreated.
  • Despite various treatments available, there is no definitive evidence on the best approach due to a lack of thorough clinical trials.
  • A case study of a 20-year-old male who underwent a personalized treatment plan using corticosteroids, surgery, and Cyclosporine A showed successful healing of the ulcer and no disease recurrence, with AS-OCT imaging helping to guide the treatment effectively.
View Article and Find Full Text PDF

Objective: Miltefosine stands as the sole oral medication approved for the treatment of leishmaniasis. The appearance of severe ophthalmic toxicities induced by miltefosine in the context of leishmaniasis treatment is a matter of significant concern. The main objective of this study is to present a comprehensive summary of the ophthalmic adverse effects associated with miltefosine when used in the treatment of leishmaniasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!